![Joosje Baltussen: Our article studying tolerability and effectiveness of Palbociclib in older women with metastatic breast cancer](https://oncodaily.com/pub/uploads/2024/04/IMG_2187-e1713538762693-1280x960.jpeg)
Photo taken from Joosje Baltussen/X
Apr 20, 2024, 06:51
Joosje Baltussen: Our article studying tolerability and effectiveness of Palbociclib in older women with metastatic breast cancer
Joosje Baltussen, Chair of Young SIOG (International Society of Geriatric Oncology) shared on X:
“Just published! Our article studying tolerability and effectiveness of Palbociclib in older women with metastatic breast cancer.
- While grade 3 toxicity occurred frequently, most were managed by dose reductions: good tolerability.
- Median PFS 12 months, median OS 31-32 months.”
Source: Joosje Baltussen/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023